Study Confirms Lebrikizumab's Safety and Effectiveness for Patients with Skin of Color and Eczema
A recent study confirms that lebrikizumab is safe and highly effective for patients with skin of color suffering from eczema, showing significant skin improvement and quality of life benefits.
Recent research published in the American Journal of Clinical Dermatology has demonstrated that lebrikizumab is both safe and effective for individuals with skin of color suffering from atopic dermatitis (AD). This open-label phase study involved 90 adolescents and adults with moderate-to-severe AD and Fitzpatrick skin phototypes IV to VI, primarily self-identifying as non-white. Participants received 250 mg of lebrikizumab via subcutaneous injection every two weeks over a 16-week period.
The study defined responders as those achieving a 75% improvement in the Eczema Area and Severity Index (EASI 75) or an Investigator's Global Assessment (IGA) score of 0/1 with at least a 2-point improvement. Those meeting these criteria received continued treatment every four weeks between weeks 16 and 24, whereas insufficient responders kept receiving biweekly doses.
Results showed significant clinical improvements: at 16 weeks, 69.2% of patients achieved EASI 75, 44.9% reached EASI 90, and 44.9% attained an IGA score of 0 or 1. Additionally, over 58% experienced notable itching relief. By week 24, these numbers increased, with 78.4% reaching EASI 75 and 54.1% attaining IGA 0/1. Patients with darker skin types (phototypes V and VI) had particularly high response rates, with over 88% achieving EASI 75.
An important observation was the reduction in hyperpigmentation, reported in 64.4% of affected patients at week 24. Furthermore, more than half of the patients expressed high satisfaction with the treatment, citing improvements not only in skin condition but also in quality of life.
This study underscores lebrikizumab's potential as a safe and effective therapy tailored for diverse populations affected by eczema. Its ability to improve clinical symptoms and hyperpigmentation in skin of color highlights its significance in personalized dermatological care.
Source: https://medicalxpress.com/news/2025-08-lebrikizumab-efficacious-safe-patients-skin.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Emerging COVID Variant NB.1.8.1 Comprises Up to One-Third of U.S. Cases
The COVID-19 variant NB.1.8.1 is rapidly spreading across the U.S., now making up nearly one-third of cases with higher transmissibility but no increased severity. Ongoing surveillance is vital to manage this evolution.
Emerging Research Highlights Potential of Ozempic and Similar Drugs in Stroke Prevention and Brain Injury Reduction
Recent research suggests that weight loss drugs like Ozempic may play a significant role in preventing strokes and reducing brain injury complications, opening new possibilities for neuroprotective therapies.